Schistosomiasis is associated with incident HIV transmission and death in Zambia

Wall, Kristin M.; Kilembe, William; Vwalika, Bellington; Dinh, Cecile; Livingston, Paul; Lee, Yeuk-Mui; Lakhi, Shabir; Boeras, Debi; Naw, Htee Khu; Brill, Ilene; Chomba, Elwyn; Sharkey, Tyronza; Parker, Rachel; Shutes, Erin; Tichacek, Amanda; Secor, W. Evan; Allen, Susan

doi:10.1371/journal.pntd.0006902

Cited by 68 publications

(76 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the eight included observational studies, seven were cross-sectional studies [18][19][20]22,[29][30][31] and one was a nested case-control study [25]. All the studies were conducted in Africa-three from Zimbabwe, two from Tanzania, one each from Ghana, South Africa and Zambia.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and meta-analysis to assess the association between urogenital schistosomiasis and HIV/AIDS infection

et al. 2020

View full text Add to dashboard Cite

Background Urogenital schistosomiasis and HIV/AIDS infections are widespread in sub-Saharan Africa (SSA) leading to substantial morbidity and mortality. The co-occurrence of both diseases has led to the possible hypothesis that urogenital schistosomiasis leads to increased risk of acquiring HIV infection. However, the available evidence concerning this association is inconsistent. The aim of this study was to systematically review and quantitatively synthesize studies that investigated the association between urogenital schistosomiasis and HIV/ AIDS infection. Methods A systematic review basing on PRISMA guidelines was conducted. It is registered with PROSPERO, number CRD42018116648. We searched four databases, MEDLINE, EMBASE, Global Health and Global Index Medicus for studies investigating the association between urogenital schistosomiasis and HIV infection. Only studies published in English were considered. Results of the association were summarised by gender. A meta-analysis was performed for studies on females using random-effects model and a pooled OR with 95% confidence interval was reported. Results Of the 993 studies screened, only eight observational studies met the inclusion criteria. Across all studies, the reported unadjusted OR ranged from 0.78 to 3.76. The pooled estimate of unadjusted OR among females was 1.31 (95% CI: 0.87-1.99). Only four of the eight studies reported an adjusted OR. A separate meta-analysis done in the three studies among females that reported an adjusted OR showed that the pooled estimate was 1.85 (95% CI: 1.17-2.92). There were insufficient data to pool results for association between urogenital schistosomiasis and HIV infection in the males.

show abstract

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

“…When a potentially relevant publication did not present needed information for meta-analysis, the authors were contacted to request additional data. If the dataset was publicly available, we obtained needed values directly [25].…”

Section: Study Selection and Data Extractionmentioning

confidence: 99%

A systematic review and meta-analysis to assess the association between urogenital schistosomiasis and HIV/AIDS infection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…FGS has been associated with infertility, a condition associated with negative social and psychological impacts in many low-income countries 6 . In addition, observational studies have suggested an association between FGS and prevalent HIV infection 7 , 8 , and HIV transmission and acquisition 9 .…”

Section: Introductionmentioning

confidence: 99%

Acceptability and feasibility of genital self-sampling for the diagnosis of female genital schistosomiasis: a cross-sectional study in Zambia

et al. 2020

View full text Add to dashboard Cite

Background: Female genital schistosomiasis (FGS) is a neglected and disabling gynaecological disorder that is difficult to diagnose and is part of the wider spectrum of urogenital disease caused by the waterborne parasite Schistosoma haematobium. Over 90% of human schistosomiasis cases are found in sub-Saharan Africa with 3.8 million people infected with schistosomes in Zambia. Reported FGS prevalence ranges from 33-75% of those with urinary schistosomiasis in endemic areas, suggesting a potentially high FGS burden in Zambia alone. The Bilharzia and HIV (BILHIV) study evaluated home self-sampling genital collection methods for the diagnosis of FGS. Methods: Eligible participants included non-pregnant, sexually active women aged 18-31 who were previously recruited for the HPTN 071 (PopART) trial in Livingstone, Zambia. Household demographic and symptom questionnaires were administered by community workers. Participants were offered vaginal and cervical self-swabs and a urine cup. Cervicovaginal lavage (CVL) was performed in clinic by midwives. Information was collected from participants on the acceptability and feasibility of genital self-sampling. Results: From January-August 2018, 603 women were enrolled, and 87.3% (527/603) completed clinic follow up. A high proportion of participants indicated that self-collection of specimens was “easy” or “very easy” on a 5-point Likert scale. A high proportion of women would be willing to self-collect all three specimens again in future: vaginal swab 96.7% (583/603), cervical swab 96.5% (582/603), and urine 96.2% (580/603). Overall, 90.0% (543/603) preferred to self-collect samples at home, compared with sampling in the clinic Home-based self-sampling was preferred over provider-based sampling in the clinic due to greater privacy 65.0% (353/543), convenience 51.4% (279/543) and lack of needed transportation 17.7% (96/543). Conclusions: Home based genital self-sampling for FGS diagnosis is highly acceptable. This scalable method may inform future efforts for community-based diagnosis of FGS

show abstract

“…Egg deposition in the liver is associated with the formation of granulomas and subsequent serious complications (1). In addition, both adult schistosomes and deposited eggs induce immunomodulatory effects that impair the host immune defenses against other pathogens, such as human immunodeficiency and hepatitis B/hepatitis C viruses (3,4).…”

Section: [Le1] [Le1]mentioning

confidence: 99%

A single oral fixed - dose praziquantel-miltefosine nanocombination for effective control of experimental Schistosomiasis mansoni

Eissa

El‐Azzouni

El-Khordagui

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Schistosomiasis control has been centered to date on praziquantel, with shortcomings involving ineffectiveness against immature worms, reinfection and emergence of drug resistance. Strategies based on drug repurposing and/or praziquantel combination therapy proved effective, though with some limitations. Combining such strategies with nanotechnology would further augment therapeutic benefits. Nanocarrier-mediated delivery of multiple drugs in schistosomiasis control has not been documented to date. Our objective was to combine drug repurposing, combinational therapy and nanotechnology for the development of a single oral fixed dose nanocombination to improve praziquantel therapeutic profile. This was based on praziquantel and an antischistosomal repurposing candidate miltefosine, co-loaded into lipid nanocapsules in reduced doses. Methods: Two fixed dose lipid nanocapsule formulations were prepared at two concentration levels of praziquantel and miltefosine. Their antischistosomal activity in comparison with control singly loaded lipoid nanocapsules was assessed in Schistosoma mansoni- infected mice. Single oral dos of 250mg praziquantel-20mg miltefosine/kg and 125mg praziquantel-10mg miltefosine/kg were administered on the initial day of infection, 21st and 42nd days post infection. Scanning electron microscopy, parasitological and histopathological studies were used for assessment. In vivo data were subjected to analysis of variance and post hoc test (Tukey) was used for pairwise comparisons. Results: Lipid nanocapsules showed a mean diameter of 58 nm and high entrapment efficiency of both drugs (>95%). Compared to singly loaded lipid nanocapsules, the larger dose praziquantel-miltefosine nanocombination exerted high antischistosomal efficacy in terms of % reduction of worm burden, particularly when given against invasive and juvenile worms, and amelioration of hepatic granulomas. Scanning electron microscopy revealed extensive tegumental damage with noticeable deposition of nanostructures. Conclusions: A fixed dose praziquantel-miltefosine nanocombination offers great potential as a novel single dose oral antischistosomal therapy offering multistage activity and protection against hepatic pathology. The novel drug repurposing/combination therapy/nanotechnology multiple approach has the potentials of improving the therapeutic profile of praziquantel, achieving radical cure, hindering resistance to the component drugs, and simplifying praziquantel chemotherapy. Key words: Praziquantel, miltefosine, lipid nanocapsules, Schistosoma mansoni, nanocombination, multistage activity, tegumental targeting, scanning electron microscopy. [LE1] [LE1]

show abstract

Schistosomiasis is associated with incident HIV transmission and death in Zambia

Cited by 68 publications

References 50 publications

A systematic review and meta-analysis to assess the association between urogenital schistosomiasis and HIV/AIDS infection

A systematic review and meta-analysis to assess the association between urogenital schistosomiasis and HIV/AIDS infection

Acceptability and feasibility of genital self-sampling for the diagnosis of female genital schistosomiasis: a cross-sectional study in Zambia

A single oral fixed - dose praziquantel-miltefosine nanocombination for effective control of experimental Schistosomiasis mansoni

Contact Info

Product

Resources

About